BioSight
Companies
GYRE THERAPEUTICS, INC. logo

GYRE

NASDAQSAN DIEGO, CA
GYRE THERAPEUTICS, INC.

Gyre Therapeutics is a clinical-stage biotech company working on gene therapy treatments, with a focus on ophthalmology based on their therapeutic areas. The company is in the process of merging with Cullgen and is navigating regulatory approval pathways including Hart-Scott-Rodino antitrust review as it advances its pipeline toward commercialization.

Price history not yet available for GYRE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar